{"name":"Brain Neurotherapy Bio, Inc.","slug":"brain-neurotherapy-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AAV2-GDNF","genericName":"AAV2-GDNF","slug":"aav2-gdnf","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AAV2-GDNF gene therapy","genericName":"AAV2-GDNF gene therapy","slug":"aav2-gdnf-gene-therapy","indication":"Parkinson's disease","status":"phase_2"}]}],"pipeline":[{"name":"AAV2-GDNF","genericName":"AAV2-GDNF","slug":"aav2-gdnf","phase":"phase_1","mechanism":"AAV2-mediated delivery of glial cell line-derived neurotrophic factor","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""},{"name":"AAV2-GDNF gene therapy","genericName":"AAV2-GDNF gene therapy","slug":"aav2-gdnf-gene-therapy","phase":"phase_2","mechanism":"AAV2-GDNF gene therapy delivers a viral vector carrying the GDNF gene to the brain, where it is expressed and promotes the survival and growth of dopaminergic neurons.","indications":["Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxORV9rNzJNLWJ2WWxXTktiM05GaUE3a3k2Z3dub2hlREZWUGdvVDBNT05Xbmh2U1lUWmFfMzFHaHhJY1Rhb2FmNWx6M3hwNW54YXQxeEZ3UFE1U1AyNy1JUVM4TTVLYVdEdGpkenJpaUZ1a2tyLUh6LWhMRGJjZVF5LUtVWmRPVTBVaXNKNXpTU2dNck5OaE1raVRYd1dwUXh4alRsemtURkZJc0VlUE1SdmpSYVpsZE16eXFuV3llaURzSVJ3MUtRYy1yYWFEaFJKZG42YndSbmhOV0U?oc=5","date":"2025-04-22","type":"pipeline","source":"PR Newswire","summary":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight - PR Newswire","headline":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPMW5Cbm9rTXB2Z3FIVEpGcmwzM1dBZ3pQY3Z4aG1oTEJMZVhMWTBwdU5vWDdpdDhDM0VqaXFFd1VFMEtSOU5fSmF0X3VzM09WZEdhQkl3cWVGTDdrRVdjTGhIRU03akRPM29UX3VzTjVMLTFrb0xUZ3cwcWgyU2tnZ0tBTEQzNkl2U3lrR0hGWWd0bkhaSFRPWmhaOFNTYXBuM0Z1ZW1QMlBISnR6WHlNUlFJVUp0T3pMMDdvRHcySFVXVExhd0VvanEyNWZNTF9LdE9ERTZuRUpqVkdfUzhFMkJ4VDQ5OUpvX1Npd1ZyNHpjTnVqZFlNYkE5U1N3MlVXYzBpd2hlNA?oc=5","date":"2025-03-03","type":"pipeline","source":"globenewswire.com","summary":"LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - globenewswire.com","headline":"LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNbjJpMUlyUXpZeHFYNUlhNDJBbWp4TXdxN3ZwZ1E5UHh6Q3lVWUhIa01QOU10VWFHWXhwTUpWZ19EV1Z3QW9EakJOUVpuUUFmREdHQnVWS3ZRN2I4WF9HVDZfODloVTg4ZTMwWG9wMUNnbEU1N1haNkJOQXRpUV9lWWVmdk1fYlpCbTlTUUtxczBObTNibWotTm9iRUFTOGpIbFpDM3BwbklBRExmUHB2d1Bialpaa1lNa1N2WnJmNzltTVFSVldfem1la3VXMG5YbkRPMlBBMVdnOHZ6MzVwWWhhWHByZ29UZ25hUnVBLWdYMWZ2OXZMVDlaZXdBdl8tSVBB?oc=5","date":"2025-02-17","type":"pipeline","source":"PR Newswire","summary":"Multiple System Atrophy Market Set to Experience Significant Growth with Breakthrough Therapies by 2034 | DelveInsight - PR Newswire","headline":"Multiple System Atrophy Market Set to Experience Significant Growth with Breakthrough Therapies by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQdzNUZFRCTVhoSUllbW1XakkxWEZseVhpUVpUMldwNkhMSGZSR0EtYlFZdTREMG5hVUpPWDRwMEJfNW94eU1JbzdXeUVubkl5MnZtUFZLWTMzME9kbW9yTnFkVWdtQjJLRjVBdWtxeHMyTDh6Rk5peXNDaHUxSWthampFTVdfbVowNExVUmFvMnpOYjlsVGs1MmpLbHlvbW56RmlBOE5zVnZzY2VVYnlrU2dST0k5RmVGTU9GdVI5eDBDd1lURE1vU2tBV1ZuR1lwUzNwanBWS29uNW5qZVVaVGtvT1VkdXVkU2swQlQxQVgtNWVkdk95UEVJUVRycDAzNk9mSjl0b1RZaXV1cGxzSlg1bUE3Q3FTWmVLVFgzWW9YQ2M5amNaeQ?oc=5","date":"2025-02-13","type":"trial","source":"globenewswire.com","summary":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - globenewswire.com","headline":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"globenewswire.com","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - globenewswire.com","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxOU1d0ZnpQRW9kcEZ3dVdhdDNhc2FpZmRXSXFpeUpsNi1ZZVduZ1lRSGdfb1drRU4tMERkSWZvZGhJRW0yQmxtSEVzeEI3UWtTbDN4a3l5UnYtbXJKeEZFdWt0U21mVXZOSVBaNWxNQ2VTMk5BMjZwVWIxcHVxMnREaUZKb3c3cUpObU9BeTVKV3Y4THBOOUwyYzlQWnVKa1FQLUNjQ2hQd2tpREp1QzhhWnFuMTFNQjN4aVA5eUJIV3B1T2IxNFNMTVZSTnZ3XzY2c2p0cUR6T2ZJbFBhTWpZR2xOdGVlVWRlRmh5WkRqQWdmT3owU1dWakdRZ1J5VnR3bTVpaDB4WnljeHpvVm5UOHRtaE9Tc3g2WEd0eG5wZnhvMGZkNWk3WWI3TkJYRDM0VXJxdlhwSDZSMlk5emFGVmJJWUpubFluUHR5alVmVTk?oc=5","date":"2024-10-14","type":"trial","source":"globenewswire.com","summary":"Tau Inhibitors Clinical Trial Pipeline Analysis - globenewswire.com","headline":"Tau Inhibitors Clinical Trial Pipeline Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNeDdqQ05ZcVhNR3FNSGg0TnR6UHJhckRJTnhPbmdkV0xUZWhiRjdmZUREdnlhbjRsZTJVaEdwUHVBMmp5N3lMckZqVVd2ZkxWX3pYOUpqdTUwUGlFRGxpcndPd1JpeTZ1dUJEbm16RlRMTmNCdk5jODFCNG1QOFRzNi1vVm9oMUhoVFJlSkc3UlI1cVdsMWxxdzBGeTFxN2F1eVVJbURHQU04SEdRSzVsS3k1UFVLc2dmQzJyRko4RlVrNW9jTTVBeXhObWhFUTRJTEtKTy1wQVJvTGpvVklqNm5jQU9qdkNSbWJKc0FHdFZlcXMtdHotdUt6ZG9hcEluWEN6YWx5cFg4bTh2TkdJRFhMWjBTMkc0c1pNX2l1Y1daU3BicnJLRWtBdjA?oc=5","date":"2023-04-19","type":"trial","source":"PR Newswire","summary":"Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight - PR Newswire","headline":"Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Workin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5sbFQzR1JrMExpYllKRzBjbWNJN2JiTDdrOU4zV2RwbWE2ZmNPVTU4Q1MzWV9OWW9SaUxjSmJGY2VOTG83Y1F2TTdKTFZNazdOUU96Vk51QlJDbFRZWVNyUzExLUM3SGh5VWlIOVJsTDdRQzFybjdNdkdHaG0xdw?oc=5","date":"2021-02-02","type":"trial","source":"Cure Parkinson's","summary":"‘AskBio’ acquires BNB and GDNF gene therapy trials - Cure Parkinson's","headline":"‘AskBio’ acquires BNB and GDNF gene therapy trials - Cure Parkinson's","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}